Noriko Motoi - Concepedia

Author

Noriko Motoi

Also Known As

Motoi, N., Motoi, Noriko, N Motoi, N. Motoi, N., Motoi, NORIKO MOTOI, Noriko MOTOI, Noriko MOTOII, Noriko Motoi, Noriko Motoi

408

Publications

13.1K

Citations

H-Index

118

Concepts

All Affiliations

Tokyo National Hospital Japanese Foundation For Cancer Research National Cancer Center Hospital East The University of Tokyo The Cancer Institute Hospital

About

Noriko Motoi is an author at Tokyo National Hospital specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	60	7.9K
2	Health Sciences	11	11	1.8K
3	Engineering	3	3	1.6K
4	Public Health	2	2	178
5	Language Studies	1	1	54

Noriko Motoi

110

Publications

10.1K

Citations

H-Index

Page 1

	Year	Citations
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib James Bean, Cameron Brennan, Jin‐Yuan Shih, Proceedings of the National Academy of Sciences Harbors Met AmplificationEngineeringPathologyTumor BiologyOncology	2007	1.6K
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Akihiko Yoshizawa, Noriko Motoi, Gregory J. Riely, Modern Pathology Further RevisionSurgical OncologyProposed Iaslc/ats/ers ClassificationMedicineMultiple Pulmonary Nodule	2011	987
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas Sizhi Paul Gao, Kevin G. Mark, Kenneth Leslie, Journal of Clinical Investigation Human Lung AdenocarcinomasOncologyCell RegulationLung InflammationMedicine	2007	656
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee André L. Moreira, Paolo Ocampo, Yuhe Xia, Journal of Thoracic Oncology Cancer DetectionGrading SystemInternational AssociationMedicineSurgical Pathology	2020	511
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Modern Pathology Tumor BiologyYoung OnsetMedicineEml4-alk Lung CancersPathology	2009	443
Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis Noriko Motoi, János Szőke, Gregory J. Riely, The American Journal of Surgical Pathology Tumor BiologyPapillary AdenocarcinomaWorld Health OrganizationOncologyMedicine	2008	372
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, Cancer Science Actionable Gene AberrationsCancer PathologyHospital‐based StudyGenetic EpidemiologyPathology	2019	351
Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease Kyuichi Kadota, Jonathan Villena‐Vargas, Akihiko Yoshizawa, The American Journal of Surgical Pathology Health SciencesAdvanced Lung DiseaseMedicineCancer RecurrenceIaslc/ats/ers Classification	2014	250
Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study Erik Thunnissen, Mary Beth Beasley, Alain Borczuk, Modern Pathology Pulmonary AdenocarcinomaTumoral PathologyMedicineSurgical PathologyHistopathology	2012	239
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors Dhananjay Chitale, Yongxing Gong, Barry S. Taylor, Oncogene Integrated Genomic AnalysisOncologyTumor HeterogeneityMedicineCancer Genomics	2009	230

Page 1